Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2015 by American Cancer Society, Inc..
Recruitment status was:  Enrolling by invitation
Queen Mary University of London
Information provided by (Responsible Party):
American Cancer Society, Inc. Identifier:
First received: December 5, 2012
Last updated: January 21, 2015
Last verified: January 2015

The LATTE study is an extension study to the now closed Arimidex, Tamoxifen Alone or in combination (ATAC) trail that took place 10 years ago. LATTE aims to collect long term follow-up information since the conclusion of ATAC, and for at least another 5 years, regarding: Additional efficacy data (first local recurrence, first distant recurrence), Additional safety data (ischaemic cardiac and cerebrovascular event, fractures), and Cause specific mortality and new primary cancers.

The LATTE study will pick up where ATAC left off to follow a number of post-menopausal women with breast cancer who were randomised to receive either anastrozole or tamoxifen in the ATAC Trial and not known to have died or withdrawn consent before April 1st 2009. Since ATAC was a nationwide study, the women of LATTE will also reside and receive their follow-up care in various areas of the country. There will not be any vulnerable groups participating in this study.

Patient interaction will consist on in person interviews at designated follow-up times and/or telephone interviews. Data will be collected at point of contact, whether that is in person at the clinic site or over the telephone. Telephone interviews will be completed in LATTE study offices. Topics of focus for data collection consists of: whether or not there is a suspected recurrence, new breast primary tumour, new other primary tumour, ischaemic cardiac event, cerebrovascular event, or a serious fracture. Since the follow-up questions are short in detail, respondent burden time should be less than 1 hour in most cases.

Breast Cancer

Study Type: Observational
Official Title: Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)

Resource links provided by NLM:

Further study details as provided by American Cancer Society, Inc.:

Primary Outcome Measures:
  • Time to recurrence [ Time Frame: LATTE particpants who are 10 years post treatment will be followed for 5 years for the purpose of this study. ]
    Time to recurrence of breast cancer in the post 10 year period (defined as the earliest of local or distant recurrence, new primary breast cancer, or death)

Estimated Enrollment: 4337
Study Start Date: October 2010
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Post-menopausal women with breast cancer who were randomised to receive either anastrozole or tamoxifen in the ATAC Trial and not known to have died or withdrawn consent before April 1st 2009 over the age of 18, living in the United States are eligible for LATTE.

Inclusion Criteria:

  • patients randomised to one of the monotherapy arms in the ATAC Trial
  • alive at 10 years follow-up

Exclusion Criteria:

  • patients who have withdrawn consent to participate in the ATAC Trial or this study
  • where the LATTE Executive Committee determines that there is no possibility of obtaining follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01745289

Sponsors and Collaborators
American Cancer Society, Inc.
Queen Mary University of London
Principal Investigator: Robert Smith, PhD American Cancer Society, Inc.
Principal Investigator: Aman Buzdar, MD M.D. Anderson Cancer Center
  More Information

Responsible Party: American Cancer Society, Inc. Identifier: NCT01745289     History of Changes
Other Study ID Numbers: IRB00050408
Study First Received: December 5, 2012
Last Updated: January 21, 2015

Keywords provided by American Cancer Society, Inc.:
Breast Cancer

Additional relevant MeSH terms:
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents processed this record on May 22, 2017